Prof. Dr. Marcus Schittenhelm
Medizinische Onkologie und Hämatologie · Dept. I
Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML).
Schittenhelm M, Kaiser M, Győrffy B, Kampa-Schittenhelm K. Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML). Cell Death Dis 2024; 15:25.
Jan 10, 2024Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML).
Jan 10, 2024Cell Death Dis 2024; 15:25
Schittenhelm Marcus, Kaiser Max, Győrffy Balázs, Kampa-Schittenhelm Kerstin
Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T, Schittenhelm M, Volken T, Lehmann T. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis. Hematology 2023; 28:2206694.
May 11, 2023Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
May 11, 2023Hematology 2023; 28:2206694
Sutter Tabea, Schittenhelm Marcus, Volken Thomas, Lehmann Thomas
Mutant driving the Warburg Effect in Mantle Cell lymphoma.
Kliebhan J, Besse A, Kampa-Schittenhelm K, Schittenhelm M, Driessen C. Mutant driving the Warburg Effect in Mantle Cell lymphoma. Clin Case Rep 2022; 10:e6296.
Oct 3, 2022Mutant driving the Warburg Effect in Mantle Cell lymphoma.
Oct 3, 2022Clin Case Rep 2022; 10:e6296
Kliebhan Johannes, Besse Andrej, Kampa-Schittenhelm Kerstin, Schittenhelm Marcus, Driessen Christoph
Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
Tsintari V, Walter B, Fend F, Overkamp M, Rothermundt C, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS). BMC cancer 2022; 22:725.
Jul 2, 2022Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
Jul 2, 2022BMC cancer 2022; 22:725
Tsintari Vasileia, Walter Bianca, Fend Falko, Overkamp Mathis, Rothermundt Christian, Lopez Charles D, Schittenhelm Marcus, Kampa-Schittenhelm Kerstin
ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
Rieger I, Tsintari V, Overkamp M, Fend F, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis. Front Mol Biosci 2021; 8:727203.
Nov 5, 2021ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
Nov 5, 2021Front Mol Biosci 2021; 8:727203
Rieger Ingmar, Tsintari Vasileia, Overkamp Mathis, Fend Falko, Lopez Charles D, Schittenhelm Marcus, Kampa-Schittenhelm Kerstin
Treatment of progressive multiple sclerosis with high-dose all-trans retinoic acid - no clear evidence of positive disease modifying effects
Ruschil C, Dubois E, Stefanou M, Kowarik M, Ziemann U, Schittenhelm M, Krumbholz M, Bischof F. Treatment of progressive multiple sclerosis with high-dose all-trans retinoic acid - no clear evidence of positive disease modifying effects. Neurol Res Pract 2021; 3:25.
May 10, 2021Treatment of progressive multiple sclerosis with high-dose all-trans retinoic acid - no clear evidence of positive disease modifying effects
May 10, 2021Neurol Res Pract 2021; 3:25
Ruschil Christoph, Dubois Evelyn, Stefanou Maria-Ioanna, Kowarik Markus Christian, Ziemann Ulf, Schittenhelm Marcus, Krumbholz Markus, Bischof Felix
Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia
Kampa-Schittenhelm K, Vogel W, Schleicher E, Bonzheim I, Mau-Holzmann U, Illing B, Akmut F, Ganief T, Dreher S, Blumenstock G, Haeusser L, Bühring H, Tsintari V, Bonin M, Haverkamp T, Schittenhelm M. Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine 2020; 54:102678.
Apr 6, 2020Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia
Apr 6, 2020EBioMedicine 2020; 54:102678
Kampa-Schittenhelm Kerstin, Vogel W, Schleicher E, Bonzheim I, Mau-Holzmann U A, Illing B, Akmut F, Ganief T, Dreher S T, Blumenstock G, Haeusser L, Bühring H J, Tsintari V, Bonin M, Haverkamp T, Schittenhelm Marcus
Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia
Schittenhelm M, Lopez C, Fend F, Mau-Holzmann U, Illing B, Akmut F, Bajrami Saipi M, Federmann B, Tsintari V, Walter B, Kampa-Schittenhelm K. Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia. EBioMedicine 2019; 42:340-351.
Apr 2, 2019Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia
Apr 2, 2019EBioMedicine 2019; 42:340-351
Schittenhelm Marcus, Lopez Charles Darin, Fend Falko, Mau-Holzmann Ulrike, Illing Barbara, Akmut Figen, Bajrami Saipi Mihada, Federmann Birgit, Tsintari Vasileia, Walter Bianca, Kampa-Schittenhelm Kerstin
Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
Kampa-Schittenhelm K, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm M. Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia. Oncotarget 2018; 9:11876-11882.
Jan 31, 2018Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
Jan 31, 2018Oncotarget 2018; 9:11876-11882
Kampa-Schittenhelm Kerstin, Vogel Wichard, Bonzheim Irina, Fend Falko, Horger Marius, Kanz Lothar, Soekler Martin, Schittenhelm Marcus
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
Kampa-Schittenhelm K, Frey J, Haeusser L, Illing B, Pavlovsky A, Blumenstock G, Schittenhelm M. Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia. Oncotarget 2017; 8:82897-82909.
Aug 7, 2017Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
Aug 7, 2017Oncotarget 2017; 8:82897-82909
Kampa-Schittenhelm Kerstin, Frey Julia, Haeusser Lara A, Illing Barbara, Pavlovsky Ashly A, Blumenstock Gunnar, Schittenhelm Marcus
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
Kampa-Schittenhelm K, Salitzky O, Akmut F, Illing B, Kanz L, Salih H, Schittenhelm M. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. BMC cancer 2016; 16:25.
Jan 16, 2016Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
Jan 16, 2016BMC cancer 2016; 16:25
Kampa-Schittenhelm Kerstin, Salitzky Olaf, Akmut Figen, Illing Barbara, Kanz Lothar, Salih Helmut Rainer, Schittenhelm Marcus
Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure
Schittenhelm M, Illing B, Ahmut F, Rasp K, Blumenstock G, Döhner K, Lopez C, Kampa-Schittenhelm K. Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure. PloS one 2013; 8:e80193.
Nov 27, 2013Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure
Nov 27, 2013PloS one 2013; 8:e80193
Schittenhelm Marcus, Illing Barbara, Ahmut Figen, Rasp Katharina Henriette, Blumenstock Gunnar, Döhner Konstanze, Lopez Charles D, Kampa-Schittenhelm Kerstin
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
Kampa-Schittenhelm K, Heinrich M, Akmut F, Rasp K, Illing B, Döhner H, Döhner K, Schittenhelm M. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer 2013; 12:46.
May 24, 2013Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
May 24, 2013Mol Cancer 2013; 12:46
Kampa-Schittenhelm Kerstin, Heinrich Michael Charles, Akmut Figen, Rasp Katharina Henriette, Illing Barbara, Döhner Hartmut, Döhner Konstanze, Schittenhelm Marcus
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
Krönke J, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk R, Döhner H, Späth D, Kapp-Schwörer S, Bullinger L, Teleanu V, Tschürtz F, Gaidzik V, Kühn M, Rücker F, Holzmann K, Paschka P, Döhner K. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013; 122:100-8.
May 23, 2013Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
May 23, 2013Blood 2013; 122:100-8
Krönke Jan, Kindler Thomas, Schittenhelm Marcus, Krauter Jürgen, Ganser Arnold, Göhring Gudrun, Schlegelberger Brigitte, Schlenk Richard F, Döhner Hartmut, Späth Daniela, Kapp-Schwörer Silke, Bullinger Lars, Teleanu Veronica, Tschürtz Florian, Gaidzik Verena I, Kühn Michael W M, Rücker Frank G, Holzmann Karlheinz, Paschka Peter, Döhner Konstanze
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Kampa-Schittenhelm K, Heinrich M, Akmut F, Döhner H, Döhner K, Schittenhelm M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer 2013; 12:19.
Mar 7, 2013Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Mar 7, 2013Mol Cancer 2013; 12:19
Kampa-Schittenhelm Kerstin, Heinrich Michael Charles, Akmut Figen, Döhner Hartmut, Döhner Konstanze, Schittenhelm Marcus
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
Hartmann J, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm M, Heeger S, Bokemeyer C. A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. Invest New Drugs 2012; 31:661-8.
Jul 26, 2012A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
Jul 26, 2012Invest New Drugs 2012; 31:661-8
Hartmann J T, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm Marcus, Heeger S, Bokemeyer C
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin
Schittenhelm M, Kampa-Schittenhelm K, Yee K, Heinrich M. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 2009; 8:2621-30.
Aug 24, 2009The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin
Aug 24, 2009Cell Cycle 2009; 8:2621-30
Schittenhelm Marcus, Kampa-Schittenhelm Kerstin, Yee Kevin W H, Heinrich Michael C
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer
Schittenhelm M, Bokemeyer C, Wong K, Corless C, Kanz L, Störkel S, Kurek R, Honecker F, Morich J, Harlow A, Oechsle K, Kollmannsberger C, Heinrich M. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther 2009; 8:481-9.
Mar 10, 2009Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer
Mar 10, 2009Mol Cancer Ther 2009; 8:481-9
Schittenhelm Marcus, Bokemeyer Carsten, Wong Kwok-Kin, Corless Christopher L, Kanz Lothar, Störkel Stephan, Kurek Raffael, Honecker Friedemann, Morich Jason, Harlow Amy, Oechsle Karin, Kollmannsberger Christian, Heinrich Michael C
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Fröhling S, Jiang J, Schittenhelm M, Lee B, Griffin J, Stone R, Heinrich M, Deininger M, Druker B, Golub T, Teckie S, Ebert B, Scholl C, Levine R, Loriaux M, Boggon T, Bernard O, Berger R, Döhner H, Döhner K, Gilliland D. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007; 12:501-13.
Dec 1, 2007Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Dec 1, 2007Cancer Cell 2007; 12:501-13
Fröhling Stefan, Jiang Jingrui, Schittenhelm Marcus, Lee Benjamin H, Griffin James D, Stone Richard M, Heinrich Michael C, Deininger Michael W, Druker Brian J, Golub Todd R, Teckie Sewit, Ebert Benjamin L, Scholl Claudia, Levine Ross L, Loriaux Marc, Boggon Titus J, Bernard Olivier A, Berger Roland, Döhner Hartmut, Döhner Konstanze, Gilliland D Gary
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)
Schittenhelm M, Cherrington J, O'Farrell A, Braziel R, Bainbridge T, Griffith D, Town A, Haley A, McGreevey L, Tyner J, Yee K, Heinrich M. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia 2006; 20:2008-14.
Sep 14, 2006FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)
Sep 14, 2006Leukemia 2006; 20:2008-14
Schittenhelm Marcus, Cherrington J M, O'Farrell A-M, Braziel R M, Bainbridge T, Griffith D J, Town A, Haley A D, McGreevey L, Tyner J W, Yee K W H, Heinrich M C